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Abstract
Personalized medicine is a new field based on molecular biology and genomics in which targeted tumor therapies are
administered to patients. Psycho-oncology is a complementary approach that considers social and psychological aspects
of patients as part of the treatments for cancer patients.
The aim of this mini-review is to weigh clinical benefits for breast cancer patients of both treatments and possibily
enhance benefits by modulating the use of both interventions. We have compared and evaluated on the one
hand the use of anti Vascular Endothelial Growth Factor and, on the other hand, psycho-oncological interventions in
metastatic and non-metastatic breast cancer patients.
Both treatments did not increase survival of metastatic breast cancer patients, while in a selected study psycho-
oncological interventions extended lifespan of non-metastatic breast cancer patients and ameliorate psychological and
social factors of metastatic breast cancer patients. Because the two approaches address completely different aspects of
cancer patients, if the comparison is limited to the extension of survival, the value of these two treatments cannot be
assessed and compared.
It is likely that by comparing patients reported outcomes, possibly by using standardized Quality of Life questionnaires,
both patients and health care providers can weigh the benefits of the two treatments. It is therefore important
to evaluate the use of cancer patients’ quality of life measures as a mean to improve their experiences about life
and treatment, and possibly to extend their survival.
Keywords: Cancer targeted drugs, Breast cancer, Psycho-oncological intervention, Psychological intervention,
Quality of life, Vascular endothelial growth factor (VEGF), Bevacizumab, Avastin, Segt
Introduction
Medicine considers the objective scientific knowledge of
biology and physiology and, on the other hand, also the
subjective personal knowledge derived from the persons
involved in the medical processes [1]. We sought to dis-
sect the dualistic epistemology of medicine that holds a
dichotomy between pure objectivity and pure subjectiv-
ity by considering the possible links between molecular
biology and psychology in the treatment of cancer pa-
tients. It is the synthesis of these far, often opposed
disciplines that is central for developing a patient-centered
medicine [2, 3]. As we show below, when molecular medi-
cine and psychology are considered as complementary
they can address care of patients in a more complex, artic-
ulated and effective manner.
One of the most promising frontiers of molecular
medicine is represented by personalized medicine. Medi-
cine is by definition, personalized, as physicians make a
diagnosis and a prognosis using information obtained
from a person’s individualized symptoms, physical char-
acteristics, health and family history, habits and expo-
sures [4]. This new discipline of personalized medicine
differs from the old, traditional medicine mainly because
it is pre-emptive, highlighting the intention to predict
the effects of the targeted intervention and its benefits
from the understanding of the molecular biology of can-
cer development [5]. In the case of the new personalized
medicine, the use of targeted drugs is only limited to the
subgroup of patients showing specific tumor genetic
variation – i.e. molecular biomarkers – that are presum-
ably associated with positive clinical outcomes. In the
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present study the choice of the anti Vascular Endothelial
Growth Factor (VEGF) targeted drug bevacizumab, for
which no molecular biomarkers have yet found was dic-
tated by the influence that psychological interventions
might have on the circulating level of this molecule (see
below the ‘discussion’ section).
The focal point of personalized medicine as defined by
the use of targeted drugs is the tumor itself, firstly evalu-
ated by using the Progression Free Survival endpoint (PFS)
and afterwards survival of patients measured through the
Overall Survival endpoint (OS), that is often coupled with
patients’ psychological status or toxicity of treatments and
related problems. These latter aspects can be addressed
through the asessement of patients’ Quality of Life (QoL).
The oncologists who, instead of prescribing medications
only, have also evaluated the psychological effects of the
oncological diagnosis and interventions on survival and
well-being of cancer patients have approached these
patients’ needs.
Psycho-oncology is a discipline which started in the
United States in mid-1970s [6] and it allows cancer pa-
tients to benefit from social and psychological programs
that contribute restoring health through alleviating the
stress caused by the diagnosis of cancer and related treat-
ments. These psycho-oncological interventions ultimately
ameliorate patients’ outcome [7]. The psycho-oncological
approach for cancer patients was mainly developed in
hospices for those patients who failed responding to
chemotherapy and where the main focus is alleviation of
symptoms. Indeed, in those cases where cancer patients
are getting closer to the final days of their lives, an ap-
proach mainly based on drug therapies is very often
detrimental to their QoL [8]. Psychosocial aspects have
played a very minor role in mainstream oncology. The
aim of this article is to complement the targeted drug
bevacizumab with psycho-oncology interventions in
breast cancer patients by reporting measures of survival
of patients (OS) and other measures related to their
psychological and social well-being.
Methods
Both, bevacizumab and psycho-oncology have been scru-
tinized using clinical trials. We formulated two ques-
tions: (i) what is the clinical trial utilized to approve
bevacizumab for metastatic breast cancer patients? And
(ii) what are the clinical trails that have been evaluating
the use of psycho-oncological interventions on breast
cancer patients and related effects on patients’ survival?
To address these questions we decided to query both,
the Food and Drug Administration (FDA) web site and
the European Medicines Agency (EMA) one to individu-
ate the trials utilized for the approval of bevacizumab for
first-line treatment of metastatic breast cancer patients
[9]. To complete the ovierview on bevacizumab we
selected, through a PubMed free search, two more trials
evaluating its use in early-stage breast cancer patients.
To analyse the psychological interventions for breast
cancer patients we developed a search algorithm, we used
in PubMed, based on key words relevant for an evaluation
of patients’ survival: (psycho-oncology [tw] OR psycho-
logic intervention [tw] OR psychosocial intervention [tw]
OR segt [tw] OR cegt [tw]) AND (breast cancer [tw])
AND (survival [tw]).
In a second step we defined criteria to determine the
relevance of retrieved articles. These criteria were defined
on the base of methodologies utilized in the articles. As
inclusion criteria we decided to focus on (i) clinical trials
measuring the effect of psychological interventions on
overall survival of breast cancer patients. We excluded
other studies than clinical trials, such as observational
studies, cohort studies, case–control studies, meta-analysis,
reviews and theoretical studies.
Moreover, we extended the search on articles con-
tained in the bibliographic references of the selected
articles, focusing on the original trials – for instance
data published on the same trials. We also searched in
PubMed for updates of those trials retrieved in the initial
search. The search was limited to articles published
untill September 15th 2015.
Besides the articles on the trials for bevacizumab and
psychosocial intervention for breast cancer patients, we
have been analyzing other theoretical articles on bio-
logical mechanisms and explanations that are at the base
of the effects elicited by these two kinds of intervention.
Furthermore, we included three meta-analysis scrutiniz-
ing the association between depression (and emotional
distress) and survival of cancer patients. Additionally, as
we found out the importance of endpoints other than
survival, we focused also on quality of life (QoL) for
breast cancer patients.
Results
One clinical trial was selected through the FDA and
EMA websites to show data utilized for the approval of
bevacizumab. The trial of Miller et al. was used for the
approval of bevacizumab for metastatic breast cancer
patients [9]. We selected two more trials through a free
PubMed search evaluating the use of bevacizumab for
early-stage cancer patients [10, 11].
The search in PubMed about psychological interven-
tions for breast cancer patients yielded 21 articles . We
selected four clinical trials to evaluate the data for the
use of psychosocial interventions on breast cancer pa-
tients. The first and the second we selected were done
on breast cancer patients, by Spiegel et al. [12], and by
Kissane et al. [13] respectively. The third and fourth se-
lected studies were done on early-stage breast cancer pa-
tients, by Andersen et al. [14] and by Kissane et al. [15]
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respectively. For gathering quantitative data on psycho-
logical interventions for breast cancer patients we ex-
cluded those articles other than clinical trials [16–32]. The
study by Spiegel et al. conducted in 1989 [12] was eventu-
ally replaced with the updated trial conducted by the same
group in 2007 [33]. We lately recovered two articles ini-
tially excluded showing biological insights useful to inter-
pret the data and develop further directions [16, 29].
Moreover, we included other two articles by Andersen et
al. to complete the data on the trial we initially selected
[34, 35]. The data on effects of bevacizumab and psycho-
logical interventions for metastatic and early-stage breast
cancer patients are systematized in Table 1.
Furthermore, we decided to include three meta-analyses
on the association between depression and survival [36–
38], and other empirical and theoretical studies on Quality
of Life of patients, as cancer diagnosis and related treat-
ments have a major negative impact on patients and the
measuring of subjective factors allows a unified evaluation
of both, targeted therapies and psychological interventions.
Bevacizumab - a targeted drug for breast cancer
The strategy of new cancer drugs consists in modifying
the deregulated intracellular pathways of cancer cells by
reprogramming the cell circuit and suppressing, among
different biological processes, the acquired neoplastic
growth caused by the sprouting of new vessels from
existing ones, a biological dynamic also known as angio-
genesis [39]. The hypothesis that cancer cells would re-
spond to the pharmacological modification of mutated
pathways is based on the notion that intracellular path-
ways mimic electronic integrated circuits. According to
this concept, cancer is a derangement of the integrated
circuit of the cell and, therefore, similar to electronic cir-
cuits, intracellular pathways should respond to a pre-
cisely defined set of rules. Anticancer drugs can then be
used to modify the mutated pathways [40, 41].
In the last decade targeted therapy for breast cancer
overexpressing the Human Epidermal Growth Factor
Receptor 2 (HER2) has been anti-HER2 agents which
improves the prognosis of early-stage breast cancer [42].
In advanced and metastatic breast cancer most of the
patients become resistant to anti-HER2 drugs; therefore,
a new therapeutic strategy was sought in these clinical
circumstances [43]. A new class of drugs has been devel-
oped to inhibit Vascular Endothelial Growth Factor
(VEGF), a diffusible protein produced by tumor cells,
that induces blood vessels formation [44]. The inhibition
Table 1 Synthesis of the data reported in selected clinical trials. Terms in bold within the 'Intervention' column indicate the specific
medical intervention/treatment assessed in the trial. Terms in bold within the 'Outcomes' column indicate the trial's endpoints





Randomized, phase 3 trial. Metastatic breast
cancer
N = 722 (Control
N = 354; Invervention
N = 368)
2.5 years PFS> 5.9 months (p < 0.001)
Efficacy and safety on paclitaxel
with or without bevacizumab
OS >1.5 months (p < 0.16)
Spiegel et al.
2007 [33]





N = 125 (Control
N = 61; Intervention
N = 64)
>1 year (14 years
follow-up)
OS <2.6 months (p = 0.73)
Kissane et al.
2007 [13]





N = 227 (Control
N = 80; Intervention
N = 147)
>1 year (2 years
follow-up)
OS >5.7 months (p = 0.60)
EORTC QoL C-30
Social functioning scale F = 4.56
(p = 0.03), Impact of Event Scale
F = 4.61 (p = 0.04)
Mini-MAC
helpless/hopelessness
F = 4.89 (p = 0.03)
Von Minckwitz
et al. 2012 [11]
Randomized clinical trial on





N = 1948 (Control
N = 969; Intervention
N = 956)
2.5 years pCR >4 % (p = 0.04)
Bear et al.
2012 [10]
Randomized clinical trial on





N = 1206 (Control
N = 596; Intervention
N = 595)
2.5 years pCR >6.3 % (p = 0.02)
Andersen et al.
2008 [14]




(stage IIA, IIIA or IIIB)
N = 227 (Control
N = 113; Intervention
N = 114)
1 year (11 years
follow-up)
OS >1.3 years (p = 0.016)
Kissane et al.
2004 [15]





(stage I or II)
N = 303 (Control
N = 149; Intervention
N = 154)
2 years (5 years
follow-up)
OS <3.5 months (p = 0.31)
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of VEGF and consequently blood vessels formation is
achieved by using anti-VEGF monoclonal antibodies, now
available on the market as bevacizumab (Avastin) [45]. As
manufacturers are under increasing pressure to demon-
strate the high clinical value of new costly therapeutics such
as bevacizumab, the use of biomarkers to target prospective
respondent cancer patients or to exclude those with a low
probability of response is a powerful method to boost effi-
cacy and reduce the wastage of resources [46]. This “selec-
tion principle” has been trying to be implemented through
the use of molecular biomarkers in order to achieve perso-
nalised cancer treatment. The great disadvantage for using
the targeted drug bevacizumab is that at present no bio-
marker is available to find the patient subgroup that will
benefit from its inclusion as a therapy [47].
Because of the unique role of angiogenesis in cancer
progression and the rationale of using anti-VEGF drugs
in advanced cancer bevacizumab was approved, through
a shortened approval, for the first line treatment of
metastatic breast cancer. The shortened process for
approval of drugs addressing serious or life threatening
diseases is guaranteed by FDA and EMA since 1992
[48]. This process was implemented in order to respond
to the increase of cancer incidence and to the needs of
patients not responding to the available therapeutics. In
this accelerated approval, the endpoints utilized in the
normal procedure have been replaced by surrogate end-
points. In the case of drugs for cancer treatments, pro-
longation of life, measured by overall survival OS, has
been substituted by progression-free survival (PFS).
Bevacizumab was approved on the basis of a clinical
trial in HER2-negative metastatic breast cancer patients
conducted by Miller et al. that showed a benefit of
5.9 months in PFS (p < 0.001) by comparing 368 patients
receiving chemotherapy with bevacizumab and 354 pa-
tients treated with chemotherapy only [9]. The signifi-
cantly prolonged PFS did not correspond to a significant
increase in OS (p < 0.16) and also subsequent studies
failed to show an OS advantage in metastatic breast can-
cer while invariably adding serious side effects, in par-
ticular hypertension. The surrogate end-point PFS is
often not linked with the golden end-point OS, confer-
ring to PFS a limited clinical value [49]. The accelerated
approval was not converted into a regular one and in
2010, after three years from its approval, the indication
for the use of bevacizumab for metastatic breast cancer
patients was revoked by the FDA [50, 51] , although still
maintained by EMA [52]. Indeed, for the shortened ap-
proval of drugs for metastatic cancer pharmaceutical
companies must first supply single-arm trials with PFS
as main end-point, then confirmatory post-approval tri-
als must be supplied. If there are no evidences for an
increase of OS of patients the indication for that specific
use is removed from the label.
‘HER2 positive’ non-metastatic breast cancer pa-
tients are eligible for anti HER2 drugs hence, on the
basis of the partial response of ‘HER2 negative’ meta-
static breast cancer to bevacizumab, its use was stud-
ied in the latter category of patients. Early-stage
cancer patients are more likely to respond to targeted
therapies as drug resistance develops at a late stage.
Bevacizumab was added to neoadjuvant chemotherapy
and the rate of pathological complete response (pCR)
was the main end-point utilized in two studies evalu-
ating the drug. In the study conducted by von Min-
ckwitz et al., the addition of bevacizumab resulted in a
moderate increase in breast pathological complete re-
sponse (pCR) from 20.6 to 24.6 % in which 956 pa-
tients who receiving bevacizumab and chemotherapy
were compared with 969 patients receiving only
chemotherapy (pCR >4 %; p = 0.04) [11]. In another
study conducted by Bear et al. the addition of bevaci-
zumab resulted in an increase in pCR from 28.2 to
34.5 % by comparing 591 patients with and without
bevacizumab (pCR >6.3 %; p = 0.02) [10]. When breast
and lymphonodes pCR was assessed, no significant in-
crease was found in both the studies. Bevacizumab
added its toxic effects to the toxicity of chemotherapy,
such as hypertension and ventricular dysfunction. Be-
cause of the short observational time, as stated by the
authors, it is not yet clear whether the neoadjuvant
effect of bevacizumab will translate into a PFS advan-
tage or into a more relevant OS increase.
Psycho-oncological intervention in breast cancer patients
Cancer patients are increasingly demanding that attention
must be given not only to the extension of life but also to
its quality related to treatment. The patients’ pressure of
considering non biological variables, together with profes-
sionals devoted to psycho-oncology are the driving force
to encourage the funding of psychosocial studies. Fur-
thermore, lately in USA, cancer centers will be required
to implement screening programs for psychosocial dis-
tress, enhancing the quality of cancer care and improv-
ing health outcomes [53]. The field of psycho-oncology
is interested in two major dimensions of cancer: (i) the
psychological responses of patients, health care pro-
viders and relatives to the disease, and (ii) the psycho-
logical, behavioral and social factors that may influence
cancer morbidity and mortality. Among the objectives
of psycho-oncology are:
 the exploration of the impact of psychological, social
and behavioral factors on survival;
 the encouragement of patients’ QoL measurements
as an outcome variable;
 the support of broad treatment goals which include
patients well-being.
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Often oncologists do not consider emotional distress of
cancer patients as part of cancer treatment [54]. Psycho-
oncological care is based on effective communication
between patients and health professionals, where effective
communication is defined as “fostering healing relation-
ships, exchanging information, responding to emotions,
managing uncertainty, making decisions and enabling
self-management” (Epstein and Street 2007 in [54]).
The psychological aspect of cancer patients has been
described as “distress” that includes everything from fear,
worry, and sadness to disabling problems such as clinical
depression, generalized anxiety and existential crisis.
Cancer patients need support to cope with their treat-
ments which in combination to the disease give rise to
detrimental effects which often require much more at-
tention than the disease itself. Social problems must be
addressed by intervening on the patients’ lifestyle such
as physical activity and change of diet with the aim of
improving physical functioning, while psychotherapy
and counseling effectively deal with distress and conse-
quently with QoL. Several studies showed that these in-
terventions can have an impact on survival [55].
Great interest for psycho-oncology arose after the pub-
lication in 1989 of a study, selected through our PubMed
search, in which OS of 86 women with metastatic breast
cancer increased by 17.7 months after enrolment in
Supported Expressive Group Therapy (SEGT) [12].
The intent of SEGT is to build new bonds of social
support, encourage expression of emotions, deal with
fears of dying, help restructure life priorities, improve
communication with family members and healthcare
professionals, and enhance control of pain and anx-
iety. The initial favorable outcome was never reproduced
and a replica of the study performed later, in 2007, re-
sulted in better OS in 125 metastatic breast cancer pa-
tients not receiving group psychotherapy. The treatment
period lasted one year but patients were encouraged to
remain in contact with the group for the entire time of the
assessment that lasted 14 years. Median survival was
30.7 months for the treatment group composed of 64
patients and 33.3 months for the control group composed
of 61 patients (OS <2.6 months; p = 0.73), but improve-
ment of patients’ well-being was not measured [33].
The second randomized clinical trial for metastatic
breast cancer patients by Kissane et al. assessed SEGT in
227 women, diagnosed with stage IV breast cancer, 80
randomized to the control group and 147 randomized to
the intervention group. Group therapy consisting of
weekly 90-minutes sessions of SEGT lasted one year
with a follow-up of 2 years [13]. The model of psycho-
logical intervention proposed by Kissane et al. was simi-
lar to the one by Spiegel et al.. The trial assessed not
only OS of patients, but contrary to the study by Spiegel
et al. it showed the effects of SEGT on depression and
other Quality of Life measures. The OS did not increase
signicantly through SEGT (median survival 24.0 months
in SEGT and 18.3 in controls, p = 0.60). Several psycho-
social well-being measures improved in women receiving
SEGT. Specifically, the clinical trial showed the manner
in which women in groups sustain humor, creativity, and
sense of purpose in their lives despite progressive illness
and frailty as they approached their death. Significant
improvement in women receiving SEGT occurred in
the EORTC (European Organization for Research and
Treatment of Cancer) QoL C-30, in the Social Func-
tioning Scale (F = 4.56; p = 0.03) and in Impact of Event
Scale (F = 4.61; p = 0.04) only for women with a base-
line diagnosis of depression. Better attitudinal coping
was evident in women receiving SEGT through reduc-
tion in scores on the helplessness-hopelessness sub-
scale (F = 4.89; p = 0.03) of the Mini-MAC (a 29-item
questionnaire on Mental Adjustement of Cancer).
In non-metastatic breast cancer patients we selected
two studies [14, 15]. The first one by Andersen et al.
tested the hypothesis that bio-behavioural or stress re-
lated factors are associated with poor survival in women
with stage IIA, IIIA or IIIB breast carcinoma. Tumor re-
currence and survival were measured in 227 randomly
selected women, 114 assigned to intervention and 113 to
assessment only [14]. Observational time ranged from 7
to 13 years, with 11 years median follow-up. Psycho-
oncological support consisted of psychological counsel-
ing, family support, and problem solving counseling.
The intervention also aimed at improving health behav-
ior through changing dietary habits, smoking cessation,
increasing daily physical exercise, progressive muscle
relaxation, support in finding ways to cope with side ef-
fects resulting from treatments such as nausea, and ad-
herence to medical treatment and follow-up. The long
observational time allowed the calculation of the median
survival time, which was 4.8 years for women in the as-
sessment only arm and 6.1 years for women receiving
psycho-oncological support (OS >1.3 years; p = 0.016).
The median time to recurrence was 2.2 years for assess-
ment only arm and 2.8 years for intervention arm [14].
Further analysis of the patients who had cancer recur-
rence showed that those receiving psycho-oncological
interventions had a lower risk of death from cancer, sur-
viving 7 months longer than those not receiving distress
reduction support with patients receiving intervention
for distress reduction reporting at 12 months a decline
in mood disturbance (Hazard Ration 0.982; p = 0.022).
Mood disturbance was assessed with The Profile of
Mood States (POMS), which is a score of five scales,
anxiety, depression, anger, fatigue and confusion [35].
The second study we selected in non-metastatic breast
cancer patients by Kissane et al. assessed the effects of
cognitive-existential group therapy (CEGT) [15]. The
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intervention was administered to 154 breast cancer pa-
tients and compared with 149 patients receiving only ad-
juvant chemotherapy (all the patients had stage I or
stage II breast cancer). The women in the intervention
group attended 20 weekly sessions lasting 90 min. The
six main goals of CEGT are promoting a supportive en-
vironment, facilitating grief, reframing negative thinking,
enhancing coping and problem solving, fostering hope,
and setting priorities for the future. Patients receiving
psychological intervention had a shorter survival of
3.6 months (p = 0.31). Although reduced anxiety was de-
tected in women receiving group therapy, survival was sig-
nificantly associated with tumor histology and node
status. Specifically, women receiving group therapy were
shown to have reduced anxiety (p = 0.05) and a trend
towards improved family functioning (p = 0.07). Also im-
portant, women receiving CEGT reported greater satisfac-
tion with their therapy and increased knowledge about
cancer and its treatment (p < 0.001) [15].
Depression and survival – meta-analyses and prospective
mechanisms
The effect of emotional distress/depression on survival
has been reported in three meta-analses. The first meta-
analysis included 157 studies and found that depression
was associated with cancer incidence (29 % elevation in
HR), survival (8 % elevation in HR) and mortality (34 %
elevation in HR) [36]. In a second meta-analysis depres-
sion, as measured by Hospital Anxiety and Depression
Scale (HADS), was associated with 25 % higher mor-
tality rate after pooling 25 studies for a total of 9417
patients [38]. Another meta-analysis confirmed that
depression was associated with a 19 % elevated mor-
tality rate in cancer patients irrespective of the sever-
ity of cancer stage [37].
Several possible plausible hypotheses have been pro-
posed to explain the improved survival in cancer pa-
tients by distress reduction. The first and most studied
mechanism is the reduction of circulating catechol-
amines, the stress hormones [56]. These hormones com-
promise cellular immunity by impairing natural killer
cells in both, the tumour microenvironment and the per-
ipheral blood; furthermore catecholamines decrease the
production of T cell [57]. Weekly sessions of psycho-
oncological intervention lasting four months, as described
above, has been shown to enhance immune response by
increasing T cell proliferation in the adjuvant setting of
non-metastatic breast cancer women [34, 57]. Interest-
ingly, bio-behavioural factors are interconnected with the
angiogenesis’ pathway, which is the target of bevacizumab.
Specifically, depression and loneliness are associated with
a higher serum level of VEGF in patients with colon can-
cer [58], and in patients with colorectal cancer subjected
to tumour resection, postoperative serum level of VEGF
was correlated with global QoL and cancer related con-
cerns [59]. Moreover, stress response and depression
involve secretion of interlukin-6 (IL-6), a pleiotropic, in-
flammatory cytokine that is also involved in t umour angio-
genesis and invasion [56]. It is likely that the release of
VEGF, that influences tumour’s vascularization and angio-
genesis, is modulated by the stress hormones, as in vitro
studies have shown that norepinephrine, a stress hormone,
stimulates the production of the angiogenic factor VEGF
through a β-adrenergic receptor [58]. Possibly, psycho-
oncological interventions reduce the circulating level of
VEGF by blocking its release induced by the stress hor-
mones. This biological effect may justify the observed
diminished cancer aggressiveness and progression after
psycho-oncological interventions.
Discussion
Personalized medicine for cancer patients through the
use of targeted drugs is a promising new therapeutic ap-
proach with a rationale of administering drugs that block
or inhibit selective molecules critical for cancer develop-
ment. Targeted drugs are modeled on receptors, signal-
ing pathways and growth factors relevant to cancer cells
growth. However, due to the fact that metastatic cancer
is a life threatening disease, the fast approval of these
drugs has been invoked as an ethical imperative [60].
One of the major obstacles for the health of cancer
patients consists in the use of medical treatments by
fragmenting the patients into the smallest biological ele-
ments [41] where psychological and social aspects of pa-
tients are eclipsed. It is important to emphasize that
patients’ psycho-oncological aspects have a direct con-
nection with the biological status of patients – as it has
been shown psycho-oncological therapy and relaxation
interventions may modify physiological stress parame-
ters, biological processes seldom studied in conjunction
with psycho-oncological interventions [61]. When ad-
ministering new drugs to cancer patients, it is first and
foremost important to consider a balance between the
efficacy of the drug and its side effects. The evaluation
of this balance is achieved by QoL measures [62]. In-
deed, the very modest benefits of Bevacizumab for
both, metastatic and non-metastatic breast cancer pa-
tients may be outweighed by the impact of side effects
and hence on QoL.
A diagnosis of cancer and the therapies that follow
have an impact not only on the physical well-being but
also on the social and emotional well-being of patients.
Social and emotional well-being is part of the QoL mea-
sures. Quality of Life is a complex amalgam of factors
divided into different domains; it is indeed a very
subjective notion. Nevertheless, there has been an ex-
tensive research to quantify subjective factors as evi-
dence for changes in patients’ QoL. By addressing
D’Abramo et al. Journal of Negative Results in BioMedicine  (2016) 15:6 Page 6 of 10
these domains, psychological interventions has ob-
tained, in non-metastatic breast cancer women, an
extension of survival [14], possibly through an effect
on stress hormones, whereas psychologic interven-
tions on metastatic breast cancer patients have ame-
liorated their social and psychological status [13]. The
European Organization for Research and Treatment
of Cancer (EORTC) has developed a scientific method
for measuring cancer patients’ QoL. The Health re-
lated Quality of Life QLQ-C30 questionnaire is a vali-
dated questionnaire and it has been translated in
more than 81 languages. The EORTC QLQ-C30 is
one of the most commonly used instruments, consist-
ing of 30 questions comprising 3 symptom scales
(Pain, Fatigue, and Nausea/Vomiting), 6 single-items
(Dyspnea, Insomnia, Appetite loss, Diarrhea, Costipa-
tion, and Financial difficulties), 5 functioning scales
(Physical, Role, Emotional, Cognitive, and Social), and
two questions referring to the overall health and qual-
ity of life [63].
Quality of Life measures and targeted drugs – an ethical
appraisal
According to our knowledge physicians mostly rely on
their subjective observations of cancer patients’ symp-
toms and QoL measures are not commonly used for
treatment with targeted therapies, despite they are in-
creasingly recognized as a valuable tool to measure ef-
fectiveness of cancer therapy [64], and in spite of the
diagnosis of cancer and related treatment that have an
impact on QoL, depending on the individual’s percep-
tion through the personal situation. Patients with cancer
are challenged by finiteness and death, so that the op-
portunity of personalized medicine, notably after a long
cancer treatment course, might seem very inviting.
The variables measured through the EORTC QLQ-
C30 were found to be significant prognostic indicators
of survival in different cancer patients although evidence
is controversial and not definitive [65, 66]. Because of
the association between QLQ-C30 measures and sur-
vival this questionnaire is included as a valuable non-
conventional endpoint in clinical trials [67]. Metastatic
breast cancer patients have a modest median survival
and in clinical trials, when survival benefit is presumably
limited, QoL assessment is particularly helpful and suit-
able. Drug ability to extend life is viewed by many oncol-
ogists and by medicine agencies as the gold standard in
assessing cancer drugs effectiveness, although for indi-
vidual management of patients QoL measures are con-
sidered the most appropriate endpoint [68, 69]. In both,
the psycho-oncology and the bevacizumab clinical trials
on metastatic breast cancer patients the main endpoint
was survival and both interventions did not attain any
increase of it. The lack of QoL measures prevented the
evaluation of emotional, social or functional patients’
improvement with psycho-oncological interventions.
Moreover, as QoL data and psychological distress both
predict OS in breast cancer patients (see the meta-
analyses above), their availability in reported trials would
have added evidence of the causes of the unsuccessful
extension of survival. The information given to and
received from cancer patients can be based on the scien-
tifically understanding of their experiences on cancer
treatments gained through QoL measures; this can not
only improve the patient-doctor relationship through
the inclusion of practitioners prone to develop a bi-
directional communication with patients, but can also
engage actively patients in their care. More relevant,
the QoL questionnaires are instruments to promote the
investigation between length and quality of survival [65],
where QoL measures open the realm to patients’ values
and expressions of their experiences. These subjective fac-
tors are assessed through scientific methods of enquiry
and represent one of the bridges between a medicine
intended as art and another one intended as science. The
objective knowledge of psychosocial aspects of medicine –
i.e. Quality of Life measures – might be instrumentally
used to modulate the pathophysiological effects of bio-
logical intervention – i.e. targeted drugs as bevacizumab.
Then, it can be ethically advisable to use both the
approaches, psychological interventions and biological tar-
geted drugs on those patients for which other drugs are
not available. Moreover, when the patient wants to partici-
pate in the decision making about her future treatments,
namely when she claims her autonomy, it is central to ac-
tivate policies to translate the information contained in
studies like this one, and focusing on treatments’ out-
comes, in a language able to convey information on spe-
cific interventions and available options [70]. From an
ethical perspective protection of vulnerable patients is of
paramount importance as their decisions on future treat-
ments might easily be bent by clinicians – advanced-stage
cancer patients develop hope in medicines alongside trust
in professional, overlooking doubts regarding drugs, trials
and clinicians [71]. Using psychological interventions
and measures on components of patients’ quality of life,
it might be possible to mitigate side-effects of cancer
therapeutics. This comprehensive, integrate approach
for cancer patients not only goes towards more effect-
ive treatments but it also represents a unification between
a medicine made of ahistorical and unnatural molecules
and a medicine rooted in humanistic values, articulated to
satisfy needs of patients [3].
The use of a standardized questionnaire, like the
EORTC QoL C-30, across different countries and sites
seems advisable. In the present study we found very dif-
ficult to compare effects derived from psychological in-
terventions on cancer patients as the endpoints were
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homogeneous – i.e. only the study by Kissane et al. on
metastatic breast cancer patients reported measures
zoperated through the EORTC QoL C-30 [13]. A pro-
spective agreement on commune measures of patients’
quality of life might be very useful in order to integrate a
QoL endpoint in clinical trials and approval processes.
Limitations
This study has limitations derived from method utilized
to gather the literature and derived from quality of data
of the article analysed. Articles selected to scrutinize the
impact of bevacizumab in early-stage non-methastatic
breast cancer patients have been chosen without a spe-
cific search strategy. Despite most of the articles on this
topic report negative and not confirmatory results, an
extended analysis might be of help for those wanting to
develop policies on the use of bevacizumab for patients
with early-stage breast cancer. For those wanting to
evaluate the controversial use of bevacizumab on endo-
crine refractory or resistant metastatic breast cancer
patients, a Cochraine review done by Wagner et al. is
worth to be considered [72]. The search strategy to re-
trieve the articles scrutinizing effects of psychological in-
terventions for breast cancer patients was limited to a
single database. Few more studies might have gained by
using other databases and auxiliary search strategies.
A second major limitation was due to the quality of
data retrieved and reported as not enriched with details
such as cancer stage and revelation index. These data
were present only in few retrieved articles. A systematic
review produced by Casellas-Grau et al. and a Cochrane
meta-analyses produced by Jassim et al., both on psycho-
logical interventions in breast cancer might very useful
to have at hand sound empirical evidences [73, 74].
Conclusion
The QoL measures are considered helpful in choosing
the right therapy for cancer patients, as psychological
distress has an impact on perceived health. It would be
therefore of pivotal interest for both, psycho-oncologists
and clinical oncologists to take into consideration a tool
to measure patients well-being in order to face the ex-
tremely difficult management of metastatic and non-
metastatic cancer patients [75]. From a prospective point
of view, if we desire to implement personalized medicine
through the use of targeted drugs, it is important to
compare and consider not only the molecular aspects of
cancer but also patients’ psychosocial health, where
communication and humanistic values are taken in con-
sideration. The incorporation of the self-reported QoL
questionnaires in clinical trials can pave the road for not
only the amelioration of patients’ symptoms but also for
an extension of their survival. The comparison between
the two different approaches through a commonly used
questionnaire can help in developing a more compre-
hensive and effective use of targeted drugs that in turn
could lead towards the validation of useful cancer bio-
markers and endpoints.
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